Immune promotive effect of bioactive peptides may be mediated by regulating the expression of SOCS1/miR‑155

Chen,Caixia; Su,Xiulan; Hu,Zhiwei

doi:10.3892/etm.2019.7734

Immune promotive effect of bioactive peptides may be mediated by regulating the expression of SOCS1/miR‑155

Authors:
- Caixia Chen
- Xiulan Su
- Zhiwei Hu
View Affiliations

Affiliations: Clinical Medicine Research Center of The Affiliated Hospital, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China
Published online on: July 5, 2019 https://doi.org/10.3892/etm.2019.7734
Pages: 1850-1862

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to evaluate the effect of bioactive hepatic peptide (BHP) on the immune function of mice and to examine the mechanism mediated by the related factors cytokine suppressor of cytokine signaling 1 (SOCS1) and microRNA (miR)‑155. The mice were divided into eight groups, including a normal mouse group, normal peptide groups (low‑dose, mid‑dose and high‑dose), an immunosuppressed group, and immunosuppressed with peptide groups (low‑dose, mid‑dose and high‑dose). The proliferative ability of splenic lymphocytes was determined in vitro using a Cell Counting kit‑8 assay. Wright's staining was used to assess the phagocytic function of macrophages. Histological changes in the spleen were evaluated by hematoxylin‑eosin staining. The relevant factors SOCS1/miR‑155 were assessed by immunohistochemistry and reverse transcription fluorescence‑quantitative polymerase chain reaction analysis. The levels of the cytokines TGF‑β1, IL‑10 and IL‑17A were determined by enzyme‑linked immunosorbent assay. First, the organ index, percentage of lymphocytes, phagocytosis experiments and splenic lymphocyte proliferation test results revealed that the immunodeficient mouse model had been successfully established. Second, compared with the control mice, the normal peptide group mice exhibited increased spleen and thymus indices, percentages of lymphocyte subsets, macrophage phagocytosis percentages, phagocytic indices, splenic lymphocyte proliferation and expression of miR‑155; however, the expression of SOCS1 was decreased in the normal peptide groups to varying extents. In addition, the expression of SOCS1 was upregulated, whereas that of miR‑155 was downregulated in the immunosuppressed group. Compared with the mice in the immunosuppressed group, the mice in the immunosuppressed with peptide groups had increased spleen and thymus indices, percentages of lymphocyte subsets, macrophage phagocytosis percentages, phagocytic indices, splenic lymphocyte proliferation and expression of miR‑155; however, the expression of SOCS1 was decreased in the immunosuppressed with peptide groups to varying extents. Following treatment with BHP, the secretion of TGF‑β1 in the spleen of the normal mice and immunosuppressed mice was significantly decreased, and the secretion of IL‑10 was significantly increased. No significant difference in the expression of IL‑17A was observed among the groups. In summary, BHP improved the immune function of the normal mice and immunosuppressed mice. This data provides a scientific basis for the development of bioactive peptide health products.

View Figures

View References

1	McKenzie CG, Guo L, Freedman J and Semple JW: Cellular immune disfunction inimmune thrombocytopenia (ITP). Br J Haematol. 163:10–23. 2013. View Article : Google Scholar : PubMed/NCBI
2	Xing Z, Yu L, Li X and Su X: Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. Cell Biosci. 6:532016. View Article : Google Scholar : PubMed/NCBI
3	Su X, Dong C, Zhang J, Su L, Wang X, Cui H and Chen Z: Combination therapy of anti-cancer bioactive peptide with Cisplatin decreases chemotherapy dosing and toxicity to improve the quality of life in xenograft nude mice bears human gastric cancer. Cell Biosci. 4:7–19. 2014. View Article : Google Scholar : PubMed/NCBI
4	Słotwiński R, Lech G and Słotwińska SM: Therapeutic microRNAs in human cancer. Cent Eur J Immunol. 43:314–324. 2018. View Article : Google Scholar : PubMed/NCBI
5	Prabahar A and Natarajan J: ImmunemiR-A database of prioritized immune miRNA disease associations and its interactome. Microrna. 6:71–78. 2017. View Article : Google Scholar : PubMed/NCBI
6	Zhang Y, Köllmer M, Buhrman JS, Tang MY and Gemeinhart RA: Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential. Peptides. 58:83–90. 2014. View Article : Google Scholar : PubMed/NCBI
7	Xiao C and Rajewsky K: MicroRNA control in the immune system: Basic principles. Cell. 136:26–36. 2009. View Article : Google Scholar : PubMed/NCBI
8	Escobar T, Yu CR, Muljo SA and Egwuagu CE: STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 54:4017–4025. 2013. View Article : Google Scholar : PubMed/NCBI
9	Preston GC, Sinclair LV, Kaskar A, Hukelmann JL, Navarro MN, Ferrero I, MacDonald HR, Cowling VH and Cantrell DA: Single cell tuning of Myc expression by antigen receptor signal strength and interleukin-2 in T lymphocytes. EMBO J. 34:2008–2024. 2015. View Article : Google Scholar : PubMed/NCBI
10	Sobhkhez M, Joensen LL, Tollersrud LG, Strandskog G, Thim HL and Jørgensen JB: A conserved inhibitory role of suppressor of cytokine signaling 1 (SOCS1) in salmon antiviral immunity. Dev Comp Immunol. 67:66–76. 2017. View Article : Google Scholar : PubMed/NCBI
11	Ma C, Wang Y, Shen A and Cai W: Resveratrol upregulates SOCS1 production by lipopolysaccharide-stimulated RAW264.7 macrophages by inhibiting miR-155. Int J Mol Med. 39:231–237. 2017. View Article : Google Scholar : PubMed/NCBI
12	Yokoyama WM, Kim S and French AR: The dynamic life of natural killer cells. Annu Rev Immunol. 22:405–429. 2004. View Article : Google Scholar : PubMed/NCBI
13	Vivier E, Tomasello E, Baratin M, Walzer T and Ugolini S: Functions of natural killer cells. Nat Immunol. 9:503–510. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW II, et al: miR-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol. 191:5904–5913. 2013. View Article : Google Scholar : PubMed/NCBI
15	Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K and Rudensky AY: Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 30:80–91. 2009. View Article : Google Scholar : PubMed/NCBI
16	Banerjee A, Schambach F, DeJong CS, Hammond SM and Reiner SL: Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol. 40:225–231. 2010. View Article : Google Scholar : PubMed/NCBI
17	Okoye IS, Czieso S, Ktistaki E, Roderick K, Coomes SM, Pelly VS, Kannan Y, Perez-Lloret J, Zhao JL, Baltimore D, et al: Transcriptomics identifieda critical role for Th2 cell-intrinsic miR-155 in mediating allergy andantihelminth immunity. Proc Natl Acad Sci USA. 111:E3081–E3090. 2014. View Article : Google Scholar : PubMed/NCBI
18	Yao R, Ma YL, Liang W, Li HH, Ma ZJ, Yu X and Liao YH: MicroRNA-155 modulates treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One. 7:e460822012. View Article : Google Scholar : PubMed/NCBI
19	Yan L, Hu F, Yan X, Wei Y, Ma W, Wang Y, Lu S and Wang Z: Inhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response. J Mol Med (Berl). 94:1063–1079. 2016. View Article : Google Scholar : PubMed/NCBI
20	Babicz-Zielinska E and Jezewska-Zychowicz M: Conceptual model of consumer's willingness to eat functional foods. Rocz Panstw Zakl Hig. 68:33–41. 2017.PubMed/NCBI
21	Bose U, Hodson MP, Shaw PN, Fuerst JA and Hewavitharana AK: Two peptide, cycloaspeptide A and nazumamide A from a sponge associated marine actinobacterium Salinispora sp. Nat Prod Commun. 9:545–546. 2014.PubMed/NCBI
22	Pessione E and Cirrincione S: Bioactive molecules released in food by lactic acid bacteria: Encrypted peptides and biogenic amines. Front Microbiol. 7:8762016. View Article : Google Scholar : PubMed/NCBI
23	Silk DB, Grimble GK and Rees RG: Protein digestion and amino acid and peptide absorption. Proc Nutr Soc. 44:63–72. 1985. View Article : Google Scholar : PubMed/NCBI
24	Su X, Chen C, Liu Q, She Y, Yan M and Hou J: Preparation method of anti-gastric cancer bioactive peptide. China Patent ZL96122236.0. Filed November 4, 1996; issued September 4, 2000.
25	Li L, Yu L, Hu J, et al: Establishment of separation and identification methods for bioactive peptide protein components. Sheng Wu Ji Shu Tong Xun. 25:682–686. 2014.
26	Crago SS, Prince SJ, Pretlow TG, McGhee JR and Mestecky J: Human colostral cells. I. Separation and characterization. Am J Clin Exp Immunol. 38:585–597. 1979.
27	Shen QC, Lin Y, Wang SY, et al: Identification and culture of Buffalo peripheral blood mononuclear macrophage. China Animal Husbandry & Veterinary Medicine. 38:31–35. 2011.
28	Stevenson HC, Katz P, Wright DG, Contreras TJ, Jemionek JF, Hartwig VM, Flor WJ and Fauci AS: Human blood monocytes: Characterization of negatively selected human monocytes and their suspension cell culture derivatives. Scand J Immunol. 14:243–256. 1981. View Article : Google Scholar : PubMed/NCBI
29	Ji H, Tian D, Zhang B, Zhang Y, Yan D and Wu S: Overexpression of miR-155 in clear-cell renal cell carcinoma and its oncogenic effect through targeting FOXO3a. Exp Ther Med. 13:2286–2292. 2017. View Article : Google Scholar : PubMed/NCBI
30	Zhang SP, Wang W, Gu Y, Jin L and Zhou F: Study on the correlation between ultrasonic imaging features in breast cancer and the expression of ER, PR, HER-2 and nm23. Biomedical Res. 28:5925–5929. 2017.
31	Ke M, Wang H, Zhou Y, Li J, Liu Y, Zhang M, Dou J, Xi T, Shen B and Zhou C: SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversedimmune suppressionvia inhibiting ROS and caspase-3 in mice. Oncotarget. 7:49509–49526. 2016. View Article : Google Scholar : PubMed/NCBI
32	Zhou G, Wang D, Liu D, Qi D and Liu Z: Expression of B and T lymphocyte attenuator in patients with severe community-acquired pneumonia and the effect of steroid therapy in a mouse model. Clin Lab. 62:2367–2377. 2016. View Article : Google Scholar : PubMed/NCBI
33	Pavić I, Katalinić-Janković V, Čepin-Bogović J, Rešić A and Dodig S: Discordance between tuberculin skin test and interferon-γ release assay in children younger than 5 years who have been vaccinated with bacillus calmette-guérin. Lab Medicine. 46:200–206. 2015. View Article : Google Scholar
34	Janossy G, Snajdr J and Simakellis M: Patterns of B-lymphocyte gene expression elicited by lipopolysaccharide mitogen. Immunology. 30:799–810. 1976.PubMed/NCBI
35	Smialek M, Tykalowski B, Dziewulska D, Stenzel T and Koncicki A: Immunological aspects of the efficiency of protectotype vaccination strategy against chicken infectious bronchitis. BMC Vet Res. 13:1–44. 2017.PubMed/NCBI
36	Yu Y, Wang H, Meng X, Hao L, Fu Y, Fang L, Shen D, Yu X and Li J: Immunomodulatory effects of cinobufagin on murine lymphocytes and macrophages. Evid Based Complement Alternat Med. 2015:8352632015. View Article : Google Scholar : PubMed/NCBI
37	Bernard M, Furlong SJ, Power Coombs MR and Hoskin DW: Differential inhibition of T lymphocyte proliferation and cytokine synthesis by [6]-Gingerol, [8]-Gingerol, and [10]-Gingerol. Phytother Res. 29:1707–1713. 2015. View Article : Google Scholar : PubMed/NCBI
38	Nicholson LB: The immune system. Essays Biochem. 60:275–301. 2016. View Article : Google Scholar : PubMed/NCBI
39	Tsai CY, Allie SR, Zhang W and Usherwood EJ: MicroRNA miR-155 affects antiviral effector and effector memoryCD8 T cell differentiation. J Virol. 87:2348–2351. 2013. View Article : Google Scholar : PubMed/NCBI
40	Shi J, Bo S and Miao M: Effect of Astragalus polysaccharide on immunological function of immunosuppressive mice induced by cyclophosphamide. Zhong Yi Xue Bao. 31:243–246. 2016.
41	Cai K, Wang X, Zhang B, et al: Effects of Curculigo chinensis polysaccharides on immune function in immunosuppressed mice induced by cyclophosphamide. Zhong Hua Zhong Yi Yao Za Zhi. 148–152. 2016.
42	Zhu X, Xu D, Chen X, et al: Immunomodulatory effects of black chicken peptide on cyclophosphamide-induced immunocompromised mice. Shi Pin Yu Fa Jiao Gong Ye. 42:44–49. 2016.
43	Zak DE, Tam VC and Aderem A: Systems-level analysis of inna-teImmunity. Annu Rev Immunol. 32:547–577. 2014. View Article : Google Scholar : PubMed/NCBI
44	Leong JW, Sullivan RP and Fehniger TA: microRNA managem-of NK-cell developmental and functional programs. Eur J Immunol. 44:2862–2868. 2014. View Article : Google Scholar : PubMed/NCBI
45	Seregin SS and Amalfitano A: Improving adenovirus based gene transfer: Strategies to accomplish immune evasion. Viruses. 2:2013–2036. 2010. View Article : Google Scholar : PubMed/NCBI
46	Gemperle C, Schmid M, Herova M, Marti-Jaun J, Wuest SJ, Loretz C and Hersberger M: Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophages. PLoS One. 7:1–6. 2012. View Article : Google Scholar
47	Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
48	Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, et al: Randomized trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas. J Clin Oncol. 34:4015–4022. 2016. View Article : Google Scholar : PubMed/NCBI
49	Wang S, Zheng Q, Tian F, et al: Changes of microRNA expression profiles during NKT cell development. Zhong Guo Mian Yi Xue Za Zhi. 33:979–984. 2017.
50	Shaohua S: Research progress in the regulation of SOCS1 on immune response in the body. Chin J Med Officer. 35:1035–1037. 2010.
51	Liu Y: Mechanism of MiR-155 regulating T cell activation. PhD dissertation, Di Er Jun Yi Da Xue. CNKI; Beijing: 2011
52	Liu Y and Cheng X: Research Progress of MicroRNA on host immunity regulation. Xian Dai Mian Yi Xue. 432–435. 2011.
53	Zhang Y, Alexander PB and Wang XF: TGF-β family signaling in the control of cell proliferation and survival. Cold Spring Harb Perspect Biol. 9(pii): a0221452017. View Article : Google Scholar : PubMed/NCBI
54	Komai T, Okamura T, Yamamoto K and Fujio K: The effects of TGF-βs on immune responses. Nihon Rinsho Meneki Gakkai Kaishi. 39:51–58. 2016. View Article : Google Scholar : PubMed/NCBI
55	Saraiva M and Garra A: The regulation of IL-10 production by immune Cells. Nat Rev Immunol. 10:170–181. 2010. View Article : Google Scholar : PubMed/NCBI
56	MacNeil IA, Suda T, Moore KW, Mosmann TR and Zlotnik A: IL-10, a novel growth cofactor for mature and immature T cells. J Immunol. 145:4167–4173. 1990.PubMed/NCBI
57	Rutz S and Ouyang W: Regulation of interleukin-10 expression. Adv Exp Med Biol. 941:89–116. 2016. View Article : Google Scholar : PubMed/NCBI
58	Cao W, Chen W, Liang X, Zhou J, Wei C, Cui S and Liu J: All-trans-retinoic acid ameliorates the inflammation by inducing transforming growth factor beta 1 and interleukin 10 in mouse epididymitis. Am J Reprod Immunol. 71:312–321. 2014. View Article : Google Scholar : PubMed/NCBI
59	Zhang X, Jiang Z, Gu Y, Liu Y, Cao X and Han Y: Inflammation-induced CD69+Kupffer cell feedback inhibits T cell proliferation via membrane-bound TGF-β1. Sci China Life Sci. 59:1259–1269. 2016. View Article : Google Scholar : PubMed/NCBI
60	Ji H, Li Y, Jiang F, Wang X, Zhang J, Shen J and Yang X: Inhibition of transforming growth factor beta⁄SMAD signal by MiR-155 is involved in arsenic trioxideinduced anti-angiogenesis in prostate cancer. Cancer Sci. 105:1541–1549. 2014. View Article : Google Scholar : PubMed/NCBI